What is the recommended ceftriaxone dose for treating uncomplicated gonorrhea in an adult (including pregnant patients), with adjustments for body weight and high-level resistance?

Ceftriaxone Dose for Gonorrhea

For uncomplicated gonorrhea in adults, administer ceftriaxone 500 mg intramuscularly as a single dose, increasing to 1 g if body weight ≥150 kg. This represents the current standard of care based on evolving antimicrobial resistance patterns and updated pharmacokinetic data 1, 2.

Standard Dosing Algorithm

For Most Adults (<150 kg)

• Ceftriaxone 500 mg IM single dose for uncomplicated urogenital, anorectal, and pharyngeal gonorrhea 1, 2
• Add doxycycline 100 mg orally twice daily for 7 days if chlamydial coinfection has not been excluded 1, 2

For Patients ≥150 kg

• Ceftriaxone 1 g IM single dose 2
• Same chlamydia coverage as above

Pregnancy Considerations

• Same dosing as non-pregnant adults (500 mg or 1 g if ≥150 kg) 3
• Ceftriaxone is safe in pregnancy; no dose adjustment needed 3
• Avoid doxycycline—substitute with azithromycin 1 g orally single dose for presumptive chlamydia treatment 4
• Pharmacokinetic modeling shows 17% reduction in overall exposure and 38% decrease in trough concentrations at 35 weeks gestation, but standard doses maintain adequate target attainment 5

Evolution of Dosing Recommendations

The dose escalation from 250 mg (2012 guidelines) 6 to 500 mg (2020 update) 1, 2 reflects critical antimicrobial stewardship principles:

Why the increase occurred:

• Ceftriaxone MICs have remained stable in the U.S. (<0.1% with "alert value" MIC >0.25 mcg/mL), but international treatment failures with 250 mg doses have been documented 2
• Pharmacodynamic modeling demonstrates that higher doses provide greater margin of safety, particularly for pharyngeal infections where tissue penetration is more variable 7, 8
• The 500 mg dose maintains 100% time above MIC for currently circulating strains, including those with elevated MICs 8, 2

Why azithromycin was removed from routine dual therapy:

• Rapid rise in azithromycin resistance (nearly 5% of isolates with MIC ≥2.0 mcg/mL by 2018) 2
• Antimicrobial stewardship concerns about unnecessary dual therapy when chlamydia is excluded 1, 2
• Ceftriaxone monotherapy remains highly effective when appropriately dosed 1, 2

Site-Specific Considerations

Pharyngeal Gonorrhea

Pharyngeal infections are particularly challenging because:

• Lower tissue concentrations of ceftriaxone in tonsillar tissue (up to 90% protein-bound) 7
• Free serum levels must remain 4× above MIC for >20 hours to achieve consistent clearance 7
• The 500 mg dose provides adequate coverage for most pharyngeal infections, but 1 g may be needed for strains with elevated MICs 7, 8

Urogenital and Anorectal Sites

• Both 500 mg and 1 g doses achieve excellent cure rates (>99%) for standard susceptible strains 8, 2
• The 500 mg dose provides sufficient pharmacodynamic coverage for current U.S. epidemiology 1, 2

High-Level Resistance Scenarios

If ceftriaxone-resistant gonorrhea is suspected or confirmed (MIC >0.125 mg/L by EUCAST criteria):

• Consider ceftriaxone 1 g IM as first-line, which can eradicate most low-level resistant strains (MIC 0.5 mg/L) 8
• For high-level resistance (MIC ≥2 mg/L), 1 g may fail, particularly for pharyngeal infections 7, 8
• Consult infectious disease specialist immediately and report to CDC through local/state health department within 24 hours 6
• Perform culture with antimicrobial susceptibility testing 6, 2
• Test-of-cure mandatory at 1 week 6

Alternative Regimens (When Ceftriaxone Unavailable or Contraindicated)

Severe Cephalosporin Allergy

• Gentamicin 240 mg IM + azithromycin 2 g orally (single doses) for azithromycin-susceptible infections 7
• Ertapenem 1 g IM daily × 3 days for resistant strains 7
• Limited data; infectious disease consultation strongly recommended 2, 9

If Ceftriaxone Temporarily Unavailable

• Cefixime 400 mg orally (single dose) is inferior to ceftriaxone, particularly for pharyngeal infections 6
• Must add azithromycin 1 g orally 6
• Mandatory test-of-cure at 1 week 6

Critical Pitfalls to Avoid

1. Do not use 250 mg dose anymore—this is outdated (pre-2020) and provides insufficient pharmacodynamic coverage 1, 2

2. Do not routinely add azithromycin unless chlamydia coinfection cannot be excluded—this promotes unnecessary resistance 1, 2

3. Do not use quinolones (ciprofloxacin, ofloxacin, levofloxacin)—widespread resistance makes these unreliable 10, 2

4. Do not assume cure without test-of-cure when using alternative regimens or treating suspected resistant infections 6, 2

5. Do not use calcium-containing diluents with ceftriaxone—precipitation can occur 3

6. In neonates, use 25-50 mg/kg (not to exceed 250 mg) as a single dose, and administer IV doses over 60 minutes to reduce bilirubin encephalopathy risk 4, 3

Treatment Failure Management

If patient returns with persistent symptoms after recommended treatment:

• Culture with susceptibility testing mandatory 6, 2
• Distinguish treatment failure from reinfection (most "failures" are reinfection) 11, 2
• Report suspected treatment failure to CDC immediately 6, 2
• Re-treat with ceftriaxone 500 mg IM (or 1 g if initially used 500 mg) + azithromycin 2 g orally 6
• Consider alternative diagnoses (C. trachomatis, M. genitalium) 11, 2